Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Nov;83(11):1132-6.
doi: 10.1111/j.1349-7006.1992.tb02735.x.

Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation

G Orengo  1 , E Noviello, G Cimoli, G Pagnan, S Parodi, M Venturini, P Conte, F Schenone, G Conzi, P Russo
Affiliations

Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation

G Orengo et al. Jpn J Cancer Res. 1992 Nov.

Abstract

Recombinant human tumor necrosis factor (rHuTNF) synergistically potentiates the cytotoxicity of the topoisomerase I inhibitor camptothecin, and the topoisomerase II inhibitors epidoxorubicin, etoposide, mitoxantrone, ellipticine, actinomycin D and 4'-(9-acridinylamino)methanesulfon-m-anisidide on A2780 human ovarian cancer cell line. Similar synergy was not observed with a combination of rHuTNF and cis-platinum or mitomycin C. When A2780 cells were incubated with rHuTNF simultaneously with camptothecin or mitoxantrone or VP16, increased numbers of DNA single-strand breaks were produced. rHuTNF alone did not induce DNA strand breakage. These data provide evidence that the enhancing effect of rHuTNF is closely related to the DNA damage mediated by topoisomerase-targeted drugs. These observations may have relevance for ovarian cancer treatment.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. ) Alexander , R. B. , Nelson , W. G. and Coffey , D. S.Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II . Cancer Res. , 47 , 2403 – 2406 ( 1987. ). - PubMed
    1. ) Coffmann , F. D. , Green , L. M. , Godwin , A. and Ware , C. F.Cytotoxicity mediated by tumor necrosis factor in variant subclones of Me‐180 cervical carcinoma line: modulation by specific inhibitors of DNA topoisomerase II . J. Cell. Biochem. , 39 , 95 – 105 ( 1989. ). - PubMed
    1. ) Utsugi , T. , Mattern , M. R. , Mirabelli , C. K. and Hanna , N.Potentiation of topoisomerase inhibitor–induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation . Cancer Res. , 50 , 2636 – 2640 ( 1990. ). - PubMed
    1. ) Baloch , Z. , Cohen , S. and Coffman , F. D.Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II . J. Immunol , 145 , 2908 – 2913 ( 1990. ). - PubMed
    1. ) Vigani , A. , Chiara , S. , Miglietta , L. , Repetto , L. , Conte , PF. , Cimoli , G. , Morelli , L. , Billi , G. , Parodi , S. and Russo , P.Effect of recombinant tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity . Gynecol. Oncol. , 41 , 52 – 55 ( 1991. ). - PubMed

Publication types

LinkOut - more resources